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Abstract 
Background: Extracellular vesicles (EVs) are small membrane‑bound vesicles which play an important role in cell‑to‑
cell communication. Their molecular cargo analysis is presented as a new source for biomarker detection, and it might 
provide an alternative to traditional solid biopsies. However, the most effective approach for EV isolation is not yet 
well established.
Results: Here, we study the efficiency of the most common EV isolation methods‑ultracentrifugation, Polyethlyene 
glycol and two commercial kits,  Exoquick® and  PureExo®. We isolated circulating EVs from the bloodstream of healthy 
donors, characterized the size and yield of EVs and analyzed their protein profiles and concentration. Moreover, we 
have used for the first time Digital‑PCR to identify and detect specific gDNA sequences, which has several implications 
for diagnostic and monitoring many types of diseases.
Conclusions: Our findings present Polyethylene glycol precipitation as the most feasible and less cost‑consuming EV 
isolation technique.
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Background
EVs are small cell-derived particles which play an impor-
tant role in cell communication and are present in all 
body fluids [1]. At least three different groups of EVs can 
be defined based on their biogenesis and size: apoptotic 
bodies, shedding microvesicles and exosomes. They all 
contain diverse cellular molecules such as nucleic acids 
(DNA, RNA, miRNA), proteins, growth factors and 
lipids, and protect them from degradation [2]. In the last 
years, the interest in studying EV cargo has increased 
significantly, mainly due to its potential use as a bio-
marker source in liquid biopsy [3].
While solid biopsies are often unavailable or have small 
size [4], the major advantage of analyzing the molecular 
cargo of EVs in blood or urine is that these samples are 
obtained by prompt and minimally invasive procedures, 
which are suitable in a clinical setting. Furthermore, EV 
content represents the intratumor heterogeneity more 
faithfully, and provides a source of diagnostic and prog-
nostic biomarkers that can be used to complement the 
patients’ data obtained by classical techniques [5].
Despite gaining tremendous scientific and clinical 
attention in the past decade, there is still no consensus 
regarding the most effective approach for EV isolation 
and their subsequent quantification and characterization. 
The original and most commonly used protocol for total 
EV isolation involves differential centrifugation and ultra-
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a sucrose or iodixanol gradient if extra pure exosome 
preparations are required [6, 7]. However, these laborious 
and time-consuming methods depend upon the utiliza-
tion of specific and expensive equipment, which hinders 
EV clinical application [8]. Also, several parameters such 
as rotor type, viscosity of the sample and centrifugation 
time [9], need to be tightly controlled in order to stand-
ardize UC-based EV isolation across the labs. These dis-
advantages may be overcome by other techniques that 
separate EVs based on their size such as ultrafiltration, 
dialysis and size exclusion chromatography, such as gel-
filtration [10–14]. These methods increase the purity 
and membrane integrity of obtained EVs, although usu-
ally render low recovery rates [15]. The immunoaffinity 
isolation uses the antibodies directed against EV sur-
face proteins to obtain specific EV types. Together with 
the use of microfluidic devices [16], these systems seem 
promising for some applications, such as proteomic EV 
analysis, although they represent expensive alternatives 
that are not intended for purification of large amounts of 
EVs [17]. In addition, immunoisolation selects only the 
positive EVs for a chosen marker, which may not reflect 
the population as a whole. Finally, precipitation solu-
tions represent an easy and fast approach for EV isolation 
which is mostly exploited by commercial kits [18]. While 
these kits are expensive, EV aggregates can be formed by 
a simple addition of polymers such as polyethylene gly-
col (PEG) and precipitated by a low-speed centrifugation 
[19].
Many efforts have been made to compare the efficiency 
of different EV isolation methods [20–24]. However, it 
still remains a challenge to decrease the inter/intra labo-
ratory variability and define the optimal isolation method 
and starting volumes needed for different downstream 
applications [25]. In addition, pre-analytical conditions, 
such as sample processing and storage, may influence EV 
analysis and need to be fully standardized prior to clinical 
application [26].
The aim of this article is to provide a comprehensive 
analysis covering the advantages and disadvantages of 
four EV isolation methods in order to define the most 
suitable method for DNA biomarkers detection in serum. 
We isolated EVs from different starting volumes of blood 
serum from healthy donors using four different tech-
niques: UC, PEG precipitation, and two commercial kits 
 (ExoQuick® and  PureExo®). We characterized the size 
and yield of enriched EVs using Nanoparticle Tracking 
Analysis (NTA), then determined their protein concen-
tration, and finally analyzed their protein content using 
western blot, flow cytometry, ELISA and an antibody 
array (Fig.  1). Our data showed that PEG yields higher 
amounts of total EVs compared with the other methods 
tested. In addition, the EVs obtained by PEG had the 
highest DNA content, as we demonstrated by digital PCR 
(dPCR). Overall, our data suggest PEG as the most fea-
sible and cost-effective isolation method, providing high 
yields of EVs suitable for DNA biomarker detection.
Results
PEG precipitation method enriches number of total 
isolated particles
The number of particles we have isolated was quantified 
using different techniques and three input serum vol-
umes. The highest recovery values were obtained with 
PEG and  Exoquick® methods.
As a first approach, we evaluated the total number of 
particles obtained per ml and effectively proved that the 
number of isolated particles depends on the amount of 
starting material used. We observed a linear correlation 
with a strong relationship between the number of parti-
cles and the serum volume (Fig.  2a). Afterwards, parti-
cles recovery and size distribution were analyzed for each 
respective isolation method (Fig. 2b). The lowest number 
of particles (7.1 × 107) was observed using 0.5 ml of input 
serum and  PureExo® method. In contrast, the highest 
yield of particles per ml (3.85 x 109) was obtained using 
2  ml of input serum and PEG. Surprisingly, we noticed 
that the UC method shows a similar number of particles 
per ml to  PureExo® in all the volumes analyzed, being sig-
nificantly lower than the values observed for  Exoquick® 
and PEG (p < 0.001). These values were two orders of 
magnitude higher when we used 0.5  ml and were more 
than 10 times higher in 1 and 2  ml. Furthermore, the 
recovery rate of particles obtained using PEG was signifi-
cantly higher than  Exoquick® (p < 0.01) (Fig. 2c).
To further calculate the average size of isolated parti-
cles, NTA diameter measurements were analyzed. As 
shown in Fig.  2d, the isolation method affects the size 
distribution profiles. These results indicated that par-
ticles isolated by UC have the largest diameter in all the 
cases studied, being significantly higher than the mean 
obtained by the other three methods for the starting vol-
ume of 0.5 ml, whereas in the case of 1 ml, significant dif-
ferences were observed only among  Exoquick® and PEG 
(p < 0.01).
Moreover, the EV concentration was assayed and quan-
tified by using the ExoELISA kit, which is based on the 
presence of the CD9 tetraspanin. The highest value was 
obtained with  Exoquick® and a 5.8-fold lower recovery 
was detected with 2 ml using the  PureExo® kit (Fig. 2e).
PEG and  Exoquick® show the highest protein quantity
To examine the efficiency of these four EV isolation 
methods, we have also compared the protein concen-
tration. For this issue, we next quantified the amount of 
protein in EV membrane and observed similar values in 
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EVs isolated by the commercial kit  Exoquick® and PEG 
except for 2 ml of starting serum, in which the concentra-
tion measures were higher in EVs isolated by  Exoquick® 
(p < 0.001). When using  PureExo® there were significant 
differences in all cases (p < 0.001), since proteins were 
only detected for the starting volumes of 2 ml (1.75 µg/
µl), but not in the other volumes. Lower protein con-
centration (p < 0.001) was detected between UC and the 
Fig. 1 Experimental procedure flowchart
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group composed by  Exoquick® and PEG in all the vol-
umes studied except in the samples obtained from UC 
and PEG with 0.5 ml of serum (p < 0.05) (Fig. 3a).
After EV lysis, we quantified the total protein extracted 
from EVs obtained by the four isolation methods. Con-
sistent with previous membrane quantification results, 
we observed lower yields of proteins using  PureExo® and 
UC as compared to  Exoquick® and PEG (p < 0.001) in 1- 
and 2-ml samples. Additionally, using 0.5  ml of serum, 
only significant differences were shown in  Exoquick® 
when samples were compared to UC and  PureExo® 
(p < 0.05) (Fig.  3b). Since the relationship between the 
number of particles and the proteins isolated is an impor-
tant factor to consider, we examined this ratio in our 
data. As shown in Fig. 3c, we observed the highest purity 
with  PureExo® followed by UC isolation method, sug-
gesting the presence of less protein contaminants with 
these methods. However, the lower values were observed 
with  Exoquick® and PEG precipitation method.
Enriched population contains EV proteins and no cellular 
contamination
To verify that our samples are enriched in typical EV 
markers, we examined the expression of the transmem-
brane tetraspanin protein CD63, by western blot. We 
detected its expression in all the volumes studied in PEG 
and  Exoquick®. However, in the case of samples isolated 
by UC, CD63 expression was only observed for the start-
ing serum volumes of 1 and 2 ml, and no signal appeared 
in  PureExo® samples (Fig. 3d). For a better characteriza-
tion of the isolated EVs, we checked the protein expres-
sion profile based on a pre-printed antibody array 
encompassing 8 EVs markers (FLOT-1, ICAM, ALIX, 
CD81, CD63, EpCam, ANXA5 and TSG101) (Fig.  4a). 
The relative expression of these markers is represented as 
a heatmap, and the four methods are classified in three 
different clusters based on their protein profile.
Figure  4b shows that PEG EV marker profiles were 
strongly correlated with the ones from  Exoquick®. 
Fig. 2 Particles size and number distribution. Correlation between the number of particles isolated and the serum volume (a). The NTA size 
distribution shows that PEG enriched a higher number of total EVs in 0.5, 1 and 2 ml (b). Total number of particles per ml quantification (c). EV size 
distribution (nm) (d). Quantitative ExoELISA assay of tetraspanin CD9. Data are shown as particles per ml (e). *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. Data 
shown as mean ± S.D. Experiments were performed in duplicate and repeated three times
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Both of them had some similarities to EVs isolated by 
 PureExo®, however the UC profile is the least correlated 
method. Additionally, we demonstrated no cellular con-
tamination in our samples, analyzing the endoplasmic 
reticulum marker calnexin by western blot, and the cis-
Golgi marker, GM130, in the antibody array (Figs. 3d, 4a).
In order to validate the results described above, we per-
formed a flow cytometry analysis of EV samples bound 
to aldehyde/sulfate latex beads. Our data confirmed 
the presence of CD63 on the surface of all EVs isolated 
(Fig. 4c).
Isolation with PEG results in a higher DNA copy number
Our last set of experiments show that PEG yielded 
the highest DNA isolation efficiency. To measure the 
recovery rate of DNA obtained, we used two different 
approaches. Firstly, we quantified the dsDNA concentra-
tion with a fluorometric assay showing non-detectable 
values in samples isolated using  PureExo® and similar 
results among the other three methods used. Significantly 
greater values were observed among  Exoquick®, PEG and 
UC using 0.5 ml of serum (p < 0.05) (Fig. 5a).
Secondly, a digital PCR was performed to demonstrate 
EV clinical utility. We analyzed the number of copies per 
µl of three genes (IDH1, BRAF and CDH4). Remarkably, 
similar values were obtained in all three probes analyzed, 
showing the high repeatability of the technique. Accord-
ing to the previous experiments, the highest DNA yield 
recovery was obtained after PEG isolation method, with 
a maximum concentration of 134.14 ± 9.43 copies of 
DNA per µl in the IDH1 gene, followed by the  Exoquick® 
method and UC. Less than one copy per µl was observed 
in the samples obtained by the commercial kit  PureExo® 
(Fig. 5b).
In summary, we have made a comparison among the 
four EV isolation methods, in which, PEG is presented as 
the most feasible EV isolation method, having the highest 
global score, followed by the high-costEV precipitation 
technique -Exoquick®-. Surprisingly, the most expensive 
commercial kit,  PureExo®, is shown as the least favour-
able choice. Although we have obtained the purest EV 
population, the number of particles, proteins and gDNA 
have displayed the lowest recovery efficiency (Table 1).
Discussion
Identification of molecular biomarkers in liquid biop-
sies from cancer patients is becoming quite  a useful 
technique. While some tumors like colorectal, breast or 
Fig. 3 Enrichment of EV markers. Membrane protein quantification (a). Total protein quantification (b). Comparison of EV Purity index (c). 
Representative western blot showing CD63 protein levels and no signal of endoplasmic reticulum (Calnexin) (d)
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Fig. 4 Exosome protein expression array (a). Heatmap of EV markers protein expression (white, none or very low expression; light blue, low 
expression; dark blue, high expression) (b). Analysis of CD63 expression by flow cytometry (c). Data are presented as mean ± S.D of three 
independent experiments, each performed in duplicate
Fig. 5 Genomic DNA quantification. Double‑stranded DNA quantification using the Qubit Fluorometer. *p ≤ 0.05, ***p ≤ 0.001 (a). Digital PCR 
analysis for the absolute quantification (copies per µl) of three different probes (IDH1, BRAF and CDH4) (b). Error bars represent standard deviation
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lung release a considerable amount of macromolecules 
to the bloodstream, others display important limita-
tions due in part to their grade, location or size [27, 28]. 
Furthermore, new approaches in the modern genomic 
medicine that require higher DNA input material are 
emerging, such as the target deep sequencing and the 
whole exome sequencing [29, 30]. Their analysis could 
help in tumor genotyping potentially leading to a suc-
cessful screening, an early diagnosis, response and fol-
low up [5, 29–35].
Thus, continuous refinement of isolation techniques in 
order to improve sensitivity and specificity of biomarker 
detection  is essential. With this challenge in mind, here 
we obtained EVs from serum of healthy donors by UC, 
two commercial kits based on polymer-based precipita-
tion reagents and PEG and compared the potential of EV 
gDNA as a biomarker source. Since there is not a well-
established technique to quantify and identify EVs [36], 
we adopted several approaches for their characterization.
Firstly, we have evaluated the number of isolated par-
ticles by NTA. We obtained the highest recovery of par-
ticles using PEG, following the same trend published by 
Tang and colleagues [37, 24]. Although PEG has recently 
been proposed as a method for EV enrichment [19], 
there is a lack of comparative studies in the literature. 
Our results point out that PEG is a real alternative to 
the expensive commercial precipitation reagents and the 
arduous UC method for EV enrichment. Furthermore, it 
has recently been presented as a scalable method for dif-
ferent volumes in other kind of samples as supernatant 
of cell and tissue cultures [38]. Consistent with the fact 
that the time and g-force used for UC method precipi-
tates EVs of all sizes, this technique yielded EVs of greater 
diameter. Furthermore, organic solvents present in other 
three methods encourage the precipitation of smaller size 
EVs, and not ABs, since their membrane composition 
is different [39]. Our findings are consistent with those 
observed in other serum samples [22].
Other indirect approaches to estimate the number of 
EVs are to measure the protein concentration and to per-
form an antibody-based quantification (ExoELISA) [40]. 
We, therefore, obtained the greatest protein recovery 
using  Exoquick®. These findings are not consistent with 
the EV numbers observed by NTA, in which the high-
est values were achieved by PEG. This might be due to 
the fact that this commercial kit may sediment contami-
nating proteins together with EVs and therefore overes-
timate the protein concentration [41, 42]. This has been 
reflected in the purity index, in which we could observe 
a slightly higher value in PEG than  Exoquick®. However, 
both isolation methods appear to precipitate more pro-
teins from the serum than UC and  PureExo®, without 
affecting the total DNA recovery. We further confirmed 
that all samples -even EVs obtained by  PureExo®- pre-
sent typical EV protein markers, such as CD63, ICAM, 
ALIX, CD81 and ANXA5, among others. Distinct protein 
profiles were observed in EVs obtained by UC. This dif-
ference is consistent with the data observed in size distri-
bution, as bigger EVs have different surface markers due 
to their different biogenesis and release mechanisms [43]. 
Furthermore, we determined our population was free 
of  cellular contamination since there was no signal for 
organelle markers Calnexin and GM130 [44]. Addition-
ally, we confirmed by flow cytometry that CD63 positive 
population values were similar to those values published 
in healthy donors [31].
Finally, the development of optimal techniques that 
provide enough genetic material is one of the main prob-
lems to overcome in liquid biopsies [45]. In this work, we 
compare DNA obtained from our samples after all four 
isolation methods and apply (for the first time to our 
knowledge) digital PCR to evaluate gDNA recovery in 
EVs.
As of yet, 0.5  ml of serum is enough to isolate suffi-
cient EV DNA to perform d-PCR, which facilitates sam-
ple collection and processing. Surprisingly, although we 
have reported lower yields of EVs in samples isolated by 
UC, we have observed similar DNA values as PEG and 
 Exoquick®. This might be explained by the presence of 
ABs carrying more DNA [46]. This is an important issue 
in this field as the genetic material comes from dying cells 
[47], thus it is not yet known if including them in a liq-
uid biopsy is a good approach for biomarkers research 
[48]. Furthermore, PEG appears to be a reasonable 
alternative to traditional methods and commercial kits, 
being cheaper, more efficient and less time consuming 
Table 1 Comparison among the different EV isolation methods with 2 ml serum
Score from 1 (the lowest) to 4 (the highest)
EVs isolation method Number of particles 
score
Size score Total protein 
score
Purity score DNA copies 
score
Price
PureExo® 1 3 1 4 1 4
Ultracentrifugation 2 4 1 3 2 1
Exoquick® 3 2 4 2 3 3
PEG 4 2 3 2 4 1
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than UC. As we have selected three genes which carry 
driver mutations relevant in several solid tumors, such 
as ovarian, lung, breast, skin and brain cancer [49–51] 
the higher gDNA values obtained by PEG present this 
method as a good approach to identify specific sequences 
to be used as prognostic, diagnostic or follow up bio-
markers. Thus,  it could help overcome the problems 
described in other methods and can be used for monitor-
ing patients [52]. Although we have previously demon-
strated the presence of gDNA inside EVs [27], it is worth 
mentioning that in the present report the main objective 
was to optimize the gDNA detection for biomarker stud-
ies, so the total gDNA obtained could be composed of EV 
and circulating gDNA [53], as no DNAse treatment has 
been used. Further investigations are needed in this field 
to address the possibility of using PEG for other down-
stream applications.
Conclusions
We have successfully shown that PEG could stand as a 
robust method to isolate gDNA-EVs reducing costs and 
time and increasing gDNA yields. Our results could serve 
as a guide for EV DNA isolation standardization, provid-
ing a minimally invasive source of biomarkers in clini-
cal practice. Our work also addresses the need to follow 
one specific isolation method depending on the research 




Pooled blood samples were obtained from 50 healthy 
donors from HM Hospitales, Madrid, Spain. Permission 
for their use was obtained from the ethical review board 
in HM Hospitales. These blood samples were left to clot 
at room temperature and serum was isolated and stored 
at − 80  °C. Three initial volumes of serum (0.5 ml, 1 ml 
and 2 ml) were compared.
EV isolation
To remove contaminating cells and cellular debris serum 
samples were centrifuged at 3000g during 15 min. For the 
UC method, serum was ultracentrifuged at 117,000g for 
90  min (Optima-LE 80  K ultracentrifuge, 55.2 Ti rotor; 
Beckman Coulter), the pellet was washed in Phosphate 
Buffered Saline 1X (PBS) (Invitrogen, 14040133), and 
ultracentrifuged again.
For the PEG method, 10% (w/v) PEG 8000 (Sigma 
Aldrich, 3015) was used to precipitate total EVs overnight 
(O/N) at 4  °C. Afterwards, the solution was centrifuged 
at 16,100g for 1 h.
Furthermore, two commercial kits (ExoQuick®; System 
Biosciences and PureExo®; 101Bio) were used according 
to the manufacturer’s instructions.
All centrifugations were performed at 4  °C. Total EVs 
were resuspended in 300 μl of PBS 1X  and stored at 
− 80 °C until use. Experiments were performed in dupli-
cate and repeated three times.
Nanoparticle Tracking Analysis (NTA)
The samples were diluted 1:1000 in PBS 1X and particles 
size and concentration were analyzed using Nanosight 
NS500 instrument (Malvern Instrument). Videos were 
recorded 3 times for each sample, 60 s each and were 
repeated 3 times at a controlled temperature of 25   °C. 
Detection threshold was increased to 5 to reduce noise. 
The results were processed using the NTA 3.1. Software.
Protein isolation and quantification
Protein concentration was determined using Bio-Rad 
Protein Assay according to the microassay procedure. 
The absorbance was then read at 595 nm in the Varios-
kan Flash (Thermo Fisher Scientific). Membrane protein 
concentration was measured directly. However, measure-
ments of  total EV protein  levels were obtained after EV 
lysis using 50 µl of EVs previously resuspended in PBS 1X 
and 50  µl of Radioimmunoprecipitation buffer (RIPA), 
(20 mM Tris pH 7.5, 150 mM NaCl, 10 mM Ethylenedi-
aminetetraacetic acid (EDTA), 1% Triton x-100, 5  mM 
NaF and protease/phosphatase inhibitor cocktail). Then, 
proteins were extracted by centrifugation at 13,200g dur-
ing 20 min at 4 °C.
Western blotting
Protein extracts (40  µl) were separated by 12% SDS-
PAGE and transferred to nitrocellulose membranes. 
After blocking for 1 h with 10% Bovine Serum Albumin 
in Tween-Tris Buffered Saline 1X (T-TBS), membranes 
were incubated with primary antibody against CD63 
(Abcam, ab8219, 1  µg/ml) O/N at 4  °C. After washing, 
membranes were incubated with a Peroxidase Horse 
anti- Mouse IgG, (1:2000, PI-2000, Vector) for 1  h at 
room temperature (RT). Detection was performed using 
ECL™ reagents according to the manufacturer’s guide-
lines (GE Healthcare).
Flow cytometry analysis of CD63
EVs samples were adsorbed onto 4% w/v, 4-µm alde-
hyde/sulfate latex beads (Thermo Fisher Scientific) for 
1 h at 4 °C. The ratio between the number of beads and 
EVs was kept constant (1:1) for all samples. The reac-
tion was stopped by adding 100 mM glycine and washed 
at 800g with 1  ml of PBS 1X. Membrane-bound beads 
were incubated with mouse anti-CD63 (1:100, 556019, 
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BD-Bioscience) for 1  h at RT and stained with a FITC-
conjugated secondary antibody (1:200, R&D Systems) for 
1  h at RT. After a final washing step, the samples were 
resuspended in 0.5 ml of PBS 1X and analyzed using the 
Attune Acoustic Focusing Cytometer (Thermo Fisher 
Scientific).
EV quantification by CD9 ELISA
The concentration of EVs was indirectly determined 
by the amount of immunoreactive EV-associated CD9 
(ExoELISA™, System Biosciences). EV samples (20  µl) 
were added to a 96-well plate and incubated at 37 °C O/N. 
Then, the plate was washed and incubated with a pri-
mary antibody (CD9) at RT for 1 h with agitation. After 
three washing steps, the samples were incubated with a 
secondary antibody (1:5000) and with super-sensitive 
TMB ELISA substrate. The absorbance was measured at 
450 nm in the Varioskan. Final results were expressed as 
number of EVs per ml of serum.
EV detection with Exo‑Check™ antibody array
A membrane-based antibody array (Exo-Check™, Sys-
tem Biosciences) was used to detect 8 known EV markers 
(FLOT-1, ICAM, ALIX, CD81, CD63, EpCAM, ANXA5 
and TSG101) following the manufacturer’s instructions. 
Briefly, 400  µg of EV protein was lysed and incubated 
O/N in the antibody membrane array. After washing 
steps, the membrane was incubated with a detection 
buffer and developed in a chemiluminescent imager.
Images were transformed to 8-bits using ImageJ. Then, 
the median value of gray intensity was measured for each 
spot. Data was normalized using the negative and posi-
tive controls of each array so that negative controls have 
a value of 0 and the positive controls a value of 100. We 
applied a hierarchical clustering to detect the relation 
between the normalized intensity of the EV markers in 
the different methods studied. The distance metric used 
was 1 minus the Pearson’s correlation coefficient.
DNA extraction and quantification
200 μl of EVs were digested with 100 μl of lysis buffer 
[(50  mM NaCl (S5886, Sigma Aldrich), 5  mM EDTA 
(E9889, Sigma Aldrich), 5  mM Tris, pH  8.0 (T6066, 
Sigma Aldrich), 1% Sodium Dodecyl Sulfate (SDS, L3771, 
Sigma Aldrich), 20  mM Dithiothreitol (DTT, 43816, 
Sigma Aldrich) and 0.5  mg/ml of Proteinase K (P4850, 
Sigma Aldrich)] O/N at 56 °C. Then, DNA extraction was 
performed using the standard phenol: chloroform: isoa-
myl alcohol procedure. DNA concentration was deter-
mined using Qubit™ dsDNA High Sensitivity assay kit 
in a Qubit™ 3.0 fluorometer (Thermo Fisher Scientific) 
according to the manufacturer’s proceedings.
Digital PCR
The digital PCR (d-PCR) was performed according to 
the reference protocol for standard and rare mutation 
using QuantStudio™ 3D Digital PCR System (Thermo 
Fisher Scientific). We combined EV DNA with nucle-
ase-free  H2O, QuantStudio™ 3D Digital PCR Master 
Mix, and the ready-to-order TaqMan Assays (20X) for 
rs6142884 (CDH4), rs28746 (IDH1) and rs113488022 
(BRAF) (Thermo Fisher Scientific). Results were analyzed 
with QuantStudio™ 3D Analysis Suite Cloud Software 
(Thermo Fisher Scientific) and the mean number of cop-
ies per µl was calculated.
Statistical analysis
Experimental results were statistically analyzed using 
ANOVA and the obtained p values were adjusted using 
Bonferroni method to counteract the multiple com-
parison problem. All the statistical analysis was per-
formed using the software package GraphPad Prism 5.0 
and values of α = 0.05 were used for hypothesis test-
ing as statistically significant levels. The data in the 
graphs are presented as mean ± SD. *p ≤ 0.05; **p ≤ 0.01; 
***p ≤ 0.001.
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